Direct Access

to personalized medicine

Idylla™

Molecular diagnostics beyond simplicity

Oncology

See how you can guide

the path her cancer takes

State-of-the-art

in-house cartridge

manufacturing line

A passionate team

driven to make a change

Biocartis

Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated and broadly applicable molecular diagnostics. Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.

Idylla™

Idylla, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer physicians fast access to highly reliable clinical molecular diagnostic information, anywhere and anytime. Idylla detects and quantifies multiple DNA or RNA-based biomarkers in a wide variety of patient sample types. The Idylla™ system’s first diagnostic tests, the Idylla™ BRAF Mutation Test for metastatic melanoma, the Idylla™ KRAS Mutation Test for colorectal cancer and the first infectious disease test, the Idylla™ Respiratory (IFV-RSV) Panel developed in collaboration with Janssen Diagnostics, have obtained CE-IVD marking.

Personalized Medicine

Personalized medicine allows making treatments more targeted to individual patient characteristics using molecular analysis. In order to make personalized medicine a sustainable reality, doctors need accurate, accessible, cost-effective molecular tests that provide correct molecular information within a reasonable time frame.